Association between blood Pentraxin-3 concentrations and rheumatic diseases: A systematic review and meta-analysis

IF 4.4 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

European Journal of Clinical Investigation Pub Date : 2024-05-29 DOI:10.1111/eci.14257

Biagio Di Lorenzo, Stefano Zoroddu, Arduino A. Mangoni, Salvatore Sotgia, Panagiotis Paliogiannis, Gian Luca Erre, Ciriaco Carru, Angelo Zinellu

{"title":"Association between blood Pentraxin-3 concentrations and rheumatic diseases: A systematic review and meta-analysis","authors":"Biagio Di Lorenzo, Stefano Zoroddu, Arduino A. Mangoni, Salvatore Sotgia, Panagiotis Paliogiannis, Gian Luca Erre, Ciriaco Carru, Angelo Zinellu","doi":"10.1111/eci.14257","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Among the Pentraxins, the long Pentraxin-3 (PTX-3) is associated with several processes, particularly in the earliest phases of the innate humoral response. Increased blood PTX-3 concentrations have been observed in a wide range of conditions, from infectious to cardiovascular disorders. Since its increase is more rapid than C-reactive protein (CRP), PTX-3 can be useful to detect and monitor early inflammation. To dissect its pathophysiological role in rheumatic diseases (RD), we conducted a systematic review and meta-analysis comparing blood PTX-3 concentrations in RD patients and healthy individuals and investigating possible associations with clinical, demographic, and study characteristics.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We performed a search of published evidence until April 2024 in PubMed, Web of Science and Scopus, which led to the selection of 60 relevant manuscripts from a total of 1072 records.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Our synthesis revealed a statistically significant difference in PTX-3 concentrations between RD patients and controls (standard mean difference, SMD = 1.02, 95% CI 0.77–1.26, <i>p</i> < .001), that correlated with CRP concentrations. The effect size was associated with geographical region of study conduction, RD type, with a reduction of the observed heterogeneity in patients with low LDL-cholesterol and triglycerides concentrations.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Our study has shown a significant increase in blood PTX-3 concentrations in RD patients, which was associated with specific patient characteristics. Nevertheless, additional studies are needed to better define the utility of measuring PTX-3 in the early phase of RD. Our study was conducted in compliance with the PRISMA 2020 statement (study protocol available at PROSPERO CRD42024516600).</p>\n </section>\n </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"54 10","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/eci.14257","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Among the Pentraxins, the long Pentraxin-3 (PTX-3) is associated with several processes, particularly in the earliest phases of the innate humoral response. Increased blood PTX-3 concentrations have been observed in a wide range of conditions, from infectious to cardiovascular disorders. Since its increase is more rapid than C-reactive protein (CRP), PTX-3 can be useful to detect and monitor early inflammation. To dissect its pathophysiological role in rheumatic diseases (RD), we conducted a systematic review and meta-analysis comparing blood PTX-3 concentrations in RD patients and healthy individuals and investigating possible associations with clinical, demographic, and study characteristics.

Methods

We performed a search of published evidence until April 2024 in PubMed, Web of Science and Scopus, which led to the selection of 60 relevant manuscripts from a total of 1072 records.

Results

Our synthesis revealed a statistically significant difference in PTX-3 concentrations between RD patients and controls (standard mean difference, SMD = 1.02, 95% CI 0.77–1.26, p < .001), that correlated with CRP concentrations. The effect size was associated with geographical region of study conduction, RD type, with a reduction of the observed heterogeneity in patients with low LDL-cholesterol and triglycerides concentrations.

Conclusions

Our study has shown a significant increase in blood PTX-3 concentrations in RD patients, which was associated with specific patient characteristics. Nevertheless, additional studies are needed to better define the utility of measuring PTX-3 in the early phase of RD. Our study was conducted in compliance with the PRISMA 2020 statement (study protocol available at PROSPERO CRD42024516600).

Abstract Image

查看原文本刊更多论文

血液中五胜肽-3 浓度与风湿病之间的关系：系统回顾和荟萃分析。

背景：在五胜肽中，长五胜肽-3（PTX-3）与多个过程有关，尤其是在先天体液反应的最初阶段。从感染性疾病到心血管疾病等多种疾病中都可观察到血液中 PTX-3 浓度的升高。由于 PTX-3 的升高比 C 反应蛋白（CRP）更快，因此可用于检测和监测早期炎症。为了剖析 PTX-3 在风湿性疾病（RD）中的病理生理作用，我们进行了一项系统回顾和荟萃分析，比较了 RD 患者和健康人血液中 PTX-3 的浓度，并调查了其与临床、人口统计学和研究特征之间可能存在的关联：我们在PubMed、Web of Science和Scopus上搜索了截至2024年4月发表的证据，从总共1072条记录中筛选出60篇相关手稿：我们的综合研究显示，RD 患者和对照组之间的 PTX-3 浓度差异具有统计学意义（标准均值差异，SMD = 1.02，95% CI 0.77-1.26，P 结论：我们的研究显示，RD 患者和对照组之间的 PTX-3 浓度显著增加：我们的研究表明，RD 患者血液中 PTX-3 浓度明显升高，这与患者的具体特征有关。然而，还需要进行更多的研究，以更好地确定在 RD 早期阶段测量 PTX-3 的效用。我们的研究符合 PRISMA 2020 声明（研究方案见 PROSPERO CRD42024516600）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Clinical Investigation 医学-医学：内科

CiteScore

9.50

自引率

3.60%

发文量

192

审稿时长

1 months

期刊介绍： EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.